Background: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients Trial Registration No: NCT01870778 (clinicaltrials.gov) Link Trial Status: Recruitment stopped, study finished Randomized in Basel 30 patients, worldwide 6800 patients Enrolling Centers: 542 centers Worldwide Core Study Team: